Oral Crizotinib induced severe esophageal ulcer with stenosis: a case report and literature review

Crizotinib is an oral [anaplastic lymphoma kinase](https://en.wikipedia.org/wiki/Anaplastic_lymphoma_kinase) and [c-ros oncogene 1](https://en.wikipedia.org/wiki/C-ros_oncogene_1) inhibitor, which is approved by the Food and Drug Administration for the treatment of metastatic non-small cell lung cancer (NSCLC). The 2011 Clinical trials demonstrated excellent treatment response, survival, and few side effects. We report a case of severe ulcerative oesophagitis with stenosis that was not reported in the 2011 Clinical trials and earlier studies.